Inventiva (NASDAQ:IVA) Sees Strong Trading Volume – Here’s What Happened

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) saw unusually-high trading volume on Wednesday . Approximately 1,886,695 shares traded hands during mid-day trading, an increase of 166% from the previous session’s volume of 709,668 shares.The stock last traded at $3.7750 and had previously closed at $3.86.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on IVA shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inventiva in a research report on Friday, July 17th. Cantor Fitzgerald began coverage on Inventiva in a research note on Friday, July 17th. They set an “overweight” rating on the stock. Guggenheim upped their target price on Inventiva from $11.00 to $14.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Piper Sandler reiterated an “overweight” rating on shares of Inventiva in a report on Wednesday. Three research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Inventiva presently has an average rating of “Buy” and a consensus target price of $15.75.

Inventiva Trading Down 1.7%

The company has a 50-day simple moving average of $4.56 and a two-hundred day simple moving average of $4.90.

Institutional Investors Weigh In On Inventiva

Several hedge funds have recently made changes to their positions in IVA. Engineers Gate Manager LP grew its stake in Inventiva by 155.5% in the second quarter. Engineers Gate Manager LP now owns 71,116 shares of the company’s stock worth $269,000 after purchasing an additional 43,280 shares during the period. Persistent Asset Partners Ltd purchased a new position in Inventiva during the fourth quarter valued at $603,000. Seven Fleet Capital Management LP purchased a new position in Inventiva during the first quarter valued at $1,111,000. Eventide Asset Management LLC bought a new stake in shares of Inventiva during the 4th quarter valued at $1,155,000. Finally, Simplify Asset Management Inc. bought a new stake in shares of Inventiva during the 4th quarter valued at $1,570,000. 19.06% of the stock is currently owned by institutional investors.

About Inventiva

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. The company develops small-molecule therapies for metabolic, liver and autoimmune diseases, with a focus on conditions that have limited treatment options.

Inventiva’s lead product candidate is lanifibranor, an oral pan-PPAR agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). The investigational therapy is intended to address liver inflammation and fibrosis associated with the disease and is being evaluated in late-stage clinical development.